That includes proactive management of side effects, candid conversations about the long-term nature of treatment, infrastructure to identify and support patients at risk of stopping and addressing the cost barriers that make GLP-1 therapy unsustainable for many. These measures are especially important, Al-Aly noted, because the cardiovascular protection provided by GLP-1 medication builds slowly, but it erodes quickly
Subsequently, in murine formalin models, intrathecal injection of GLP-1(736) at a variety of doses significantly reduced the tonic flinching response in a dose-dependent manner, with no effects on acute nociceptive responses [24]
It has no completed human clinical trials measuring fat loss outcomes, and it is not FDA-approved for weight management or any other therapeutic use
The routine stays clear whether the plan stays the same, slows down, or changes later
Most patients notice changes in appetite and food-related thoughts within the first few weeks of treatment, though the full effect on food noise typically develops over several weeks to months as doses are gradually increased to therapeutic levels
JCI Insight (2020) 4
